Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Toshiki Miyazaki x
  • Refine by access: All content x
Clear All Modify Search
Toshiki Miyazaki First Institute of New Drug Discovery, Qs' Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno Kawauchi-cho, Tokushima 771-0192, Japan

Search for other papers by Toshiki Miyazaki in
Google Scholar
PubMed
Close
,
Koji Ohmoto First Institute of New Drug Discovery, Qs' Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno Kawauchi-cho, Tokushima 771-0192, Japan

Search for other papers by Koji Ohmoto in
Google Scholar
PubMed
Close
,
Tsuyoshi Hirose First Institute of New Drug Discovery, Qs' Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno Kawauchi-cho, Tokushima 771-0192, Japan

Search for other papers by Tsuyoshi Hirose in
Google Scholar
PubMed
Close
, and
Hiroyuki Fujiki First Institute of New Drug Discovery, Qs' Research Institute, Otsuka Pharmaceutical Co., Ltd, 463-10 Kagasuno Kawauchi-cho, Tokushima 771-0192, Japan

Search for other papers by Hiroyuki Fujiki in
Google Scholar
PubMed
Close

The effects of stable chronic hyponatremia on the central nervous system are largely unknown, clinically, or in experimental animals. The aim of this study was to identify and characterize these effects in rats. Tolvaptan, a vasopressin V2 receptor antagonist, was used to correct hyponatremia and determine any potential benefits of such treatment in this condition. Stable chronic hyponatremia was induced by combination of the continuous vasopressin V2 receptor stimulation and liquid food intake. The hyponatremic rats did not exhibit significant changes in general symptoms or neurological functions assessed by modified Irwin's method, or in motor function assessed by the rotarod test. In passive avoidance test, however, rats with moderate and severe hyponatremia had significantly reduced step-through latency, indicating impairment in memory. This reduced step-through latency was improved by the treatment of tolvaptan (0.25–8 mg/kg daily doses), a vasopressin V2 receptor antagonist. This improvement is associated with normalization of plasma sodium concentrations in hyponatremic rats. In conclusion, these data suggest that chronic hyponatremia may impair memory, and treatments that normalize sodium level, such as vasopressin V2 receptor antagonists, may be beneficial to patients with hyponatremia.

Free access